(Q37304301)

English

Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

scientific article published on 20 October 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

6 references

13 March 2019

17 June 2019

9 October 2019

7 November 2019

12 November 2019

26 October 2020

0 references

Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

0 references

interstitial lung disease

6 references

13 March 2019

17 June 2019

9 October 2019

7 November 2019

12 November 2019

26 October 2020

systemic scleroderma

6 references

13 March 2019

17 June 2019

9 October 2019

7 November 2019

12 November 2019

26 October 2020

respiratory system

1 reference

9 October 2019

1 reference

7 November 2019

organic compound, having C-P covalent bound

1 reference

12 November 2019

immunosuppressive drug

1 reference

26 October 2020

systematic review

1 reference

based on heuristic

inferred from title

3

object named as

Patricia J Erwin

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

2

object named as

Colin P West

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Carlotta Nannini

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Eric L Matteson

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

20 October 2008

7 references

Europe PubMed Central

PMC publication ID

19 August 2017

13 March 2019

17 June 2019

9 October 2019

7 November 2019

12 November 2019

26 October 2020

Arthritis Research and Therapy

7 references

Europe PubMed Central

PMC publication ID

19 August 2017

13 March 2019

17 June 2019

9 October 2019

7 November 2019

12 November 2019

26 October 2020

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

R124

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

6 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

9 October 2019

Europe PubMed Central

7 November 2019

Europe PubMed Central

12 November 2019

Europe PubMed Central

26 October 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

https://scigraph.springernature.com/pub.10.1186/ar2534

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Scleroderma lung: pathogenesis, evaluation and current therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

New therapeutic strategies for systemic sclerosis--a critical analysis of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Interstitial lung disease in the patient who has connective tissue disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Evaluation and management of alveolitis and interstitial lung disease in scleroderma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Interstitial lung disease in scleroderma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid Arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

6 September 2017

Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

26 June 2018

Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

2 September 2018

Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

2 September 2018

A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

2 September 2018

Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

2 September 2018

Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

2 September 2018

Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592814

2 September 2018

Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists

1 reference

https://pubmed.ncbi.nlm.nih.gov/18937831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18937831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18937831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18937831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18937831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18937831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre

1 reference

https://pubmed.ncbi.nlm.nih.gov/18937831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase

1 reference

https://pubmed.ncbi.nlm.nih.gov/18937831

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37304301&oldid=2153456459"